Overall survival results from ICON8, a GCIG phase 3 randomised controlled trial assessing weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment

Autor: McNeish, I, Clamp, A, James, EC, Dean, A, Kim, J-W, O’Donnell, DM, Gallardo-Rincon, D, Blagden, S, Brenton, J, Perren, TJ, Sundar, S, Lord, R, Dark, G, Hall, M, Banerjee, S, Glasspool, RM, Hanna, L, Williams, S, Scratchard, KM, Nam, H, Essapen, S, Parkinson, C, McAvan, L, Swart, AM, Popoola, B, Schiavone, F, Badrock, J, Fananapazir, F, Cook, AD, Parmar, M, Kaplan, R, Ledermann, JA

Background: Standard of care first line chemotherapy for epithelial ovarian cancer (EOC) is carboplatin and paclitaxel administered once every three weeks. The JGOG3016 trial reported significant improvement in progression-free (PFS) and overall surv

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::17c3c5e9aea946d9d3b2babae950d996
http://hdl.handle.net/10044/1/97299

An exploratory analysis of objective responses to neoadjuvant chemotherapy: results from a randomised phase III trial evaluating first-line carboplatin-paclitaxel regimens for ovarian, fallopian tube or primary peritoneal carcinoma (ICON8)

Autor: McNeish, I, Morgan, RD, Cook, AD, James, EC, Lord, R, Dark, G, Glasspool, RM, Krell, J, Parkinson, C, Poole, CJ, Hall, M, Gallardo-Rincón, D, Lockley, M, Essapen, S, Summers, J, Anand, A, Zachariah, A, Williams, S, Jones, R, Scatchard, K, Walther, A, Kim, J-W, Sundar, S, Jayson, GC, Ledermann, JA, Clamp, AR

BackgroundPlatinum-based neoadjuvant chemotherapy (NACT) followed by delayed primary surgery (DPS) is an established strategy for women with newly diagnosed, advanced stage epithelial ovarian cancer. Although this therapeutic approach has been valida

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1032::9636d15c7a38b268fbe7c56d2b27da23
http://hdl.handle.net/10044/1/83730

Quality of life of weekly, dose-dense versus standard chemotherapy for ovarian cancer in the ICON8 study

Autor: Blagden, S, Cook, A, Poole, C, Howells, L, McNeish, I, Dean, A, Galardo, D, Kim, J, O'Donnell, D, Hook, J, James, E, Perren, T, Lord, R, Dark, G, Earl, H, Hall, M, Kaplan, R, Ledermann, J, Clamp, A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::b416d9f873edef5d3effafa0e55a6ade
https://ora.ox.ac.uk/objects/uuid:0d8179f8-b478-405a-a52c-97c4b86c92d5

Differentiation and Definition of Vascular-Targeted Therapies

Autor: Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Michael Horsman, Marmé, D., Lorusso, P. M.

Publikováno v: Scopus-Elsevier
Siemann, D W, Bibby, M C, Dark, G G, Dicker, A P, Eskens, F A L M, Horsman, M R, Marmé, D & LoRusso, P M 2005, ' Differentiation and definition of vascular-targeted therapies ', Clinical Cancer Research, vol. 11, no. 2 Pt 1, pp. 416-420 . < http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15701823&query_hl=53&itool=pubmed_docsum >
Clinical Cancer Research, 11, 416-420. American Association for Cancer Research Inc.

The therapeutic potential of targeting the tumor vascular supply is now widely recognized. Intense research and development activity has resulted in a variety of investigational agents, a number of which are currently in clinical development. As thes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fef411d0252696c3e487e92ae9bd8475
https://doi.org/10.1158/1078-0432.416.11.2

943PD - Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment

Autor: Clamp, A.R., McNeish, I.A., Dean, A., Gallardo-Rincon, D., Kim, J.-W., O’Donnell, D.M., Hook, J., Blagden, S., Brenton, J.D., Naik, R., Perren, T.J., Sundar, S., Cook, A.D., James, E.C., Gabra, H., Lord, R., Hall, M., Dark, G., Kaplan, R.S., Ledermann, J.A.

Publikováno v: In Annals of Oncology October 2018 29 Supplement 8